Docstoc

Pharm Exec - Pharmaceutical Executive

Document Sample
Pharm Exec - Pharmaceutical Executive Powered By Docstoc
					                                                                                                 NO
#   PHARMACEUTICAL EXECUTIVE




                                                                                                           S


Nothing works              for you like a network that works together   THE AUTHENTIC INTEGRATED NETWORK
                                                                          BOEHRINGER-INGELHE
OVO NORDISK
                                                                                                   MAY 2008 www.pharmexec.com        75




  T
         he Pharm Exec 50 for 2008 ac-
         counted for prescription drug sales
                                                  we assembled this year’s 50. In the past,
                                                  private companies that did not disclose

                                                                                              PFIZER
                                                                                               THE PHARM EXEC 50
                                                                                               1. Pfizer




                                                  TAKEDA
         of more than $510 billion. Inter-        sales figures were omitted. Starting         2. GlaxoSmithKline
    estingly, except for Pfizer, GSK, Sanofi-     this year, we’re offering estimates. This    3. Sanofi-Aventis
    Aventis (numbers one through three,           mostly affects privately owned European      4. Novartis
    respectively), and Watson (number 50),        companies such as Menarini, Servier,         5. AstraZeneca
    every company on the list showed posi-        and Ratiopharm, though it also means a       6. Johnson & Johnson
    tive growth last year, including some         first time ranking for Procter & Gamble,     7. Merck
    solid double-digit performances.              whose multi-billion dollar pharmaceuti-      8. Roche




SCHERING-PL
       Much of that growth was driven by          cal operation is such a small part of the    9. Wyeth
    mergers, of which there were many. Ny-        company that P&G declines to break out       10. Eli Lilly
    comed, for example, almost tripled in size    the figures by sales of human prescrip-      11. Bristol-Myers Squibb
                                                                                               12. Bayer
    after its purchase of Altana, itself a top    tion drugs and vaccines, as reported in
                                                                                               13. Abbott
    50 company. And because rankings in the       annual reports and SEC filings.
                                                                                               14. Amgen
    Pharm Exec 50 are calculated in US dol-           We do not count royalty revenue, con-
                                                                                               15. Boehringer-Ingelheim
    lars, a number of European companies          tract manufacturing, or animal health,
                                                                                               16. Schering-Plough
    look better than they might have if re-       and OTC is excluded as far as the docu-
                                                                                               17. Takeda
    ported in their native currencies. (Roche’s   ments allow. Some accompanying charts
                                                                                               18. Genentech
    prescription drug revenue, for instance,      are based on figures from IMS health.        19. Teva
    grew by 11 percent in Swiss francs, but       These are calculated differently, and        20. Novo Nordisk
    more than 20 percent in US dollars.)          may disagree with numbers cited in the       21. Astellas
       We made one key change in the way          50 itself.                                   22. Daiichi Sankyo
                                                                                               23. Merck KGaA




                                  GENENTECH
    PHARM EXEC TOP 50                                                                          24. Eisai




    theWINNeRS’
                                                                                               25. Otsuka
                                                                                               26. Servier
                                                                                               27. UCB
                                                                                               28. Baxter
                                                                                               29. Nycomed
                                                                                               30. Solvay




                                       CIRCLe BAYER
                                                                                               31. Gilead Sciences




       $ $ $
                                                                                               32. Genzyme
                                                                                               33. Forest
                                                                                               34. Menarini
                                                                                               35. Allergan
                                                                                               36. Mitsubishi Tanabe
                                                                                               37. Chugai
                                                                                               38. P&G
    Pharma may be taking a hit, but a                                                          39. Ratiopharm
                                                                                               40. CSL
    surprising number of the Pharm Exec 50                                                     41. Barr Pharmaceuticals

    turned in double-digit growth last year.
                                                                                               42. Alcon
                                                                                               43. Mundipharma

    Sure, some of that is a matter of mergers                                                  44. Shire




                  ROCHE
                                                                                               45. Biogen Idec




                                                                                     LILLY
    and the falling dollar, and the giants at                                                  46. Stada
                                                                                               47. King Pharmaceuticals

    the top of the list actually lost sales. But                                               48. Lundbeck
                                                                                               49. Actavis
    the industry’s elite still features players                                                50. Watson


    who know how to hit the bullseye.
    BY PHARM EXEC STAFF

 Nothing works            for you like a network that works together                                     THE AUTHENTIC INTEGRATED NETWORK
76
            PE50
     PHARMACEUTICAL EXECUTIVE                                                                                                  MAY 2008 www.pharmexec.com




      Rank                Company & Headquarters                        2007 Global Pharma R&D Spend                   2007 Top-Selling Drugs
      [‘06 Rank]          [Web site]                                    Sales [change from 2006]                       [2007 sales]



      1   [1]
                          Pfizer
                          New York, NY [pfizer.com]
                                                                        $44.4 B [-1.5%]            $8.1 B              Lipitor [$12.7 B]
                                                                                                                       Norvasc [$3.0 B]
                                                                                                                       Celebrex [$2.3 B]


      2   [2]
                          GlaxoSmithKline
                          London, England [gsk.com]
                                                                        $38.2 B [-2.7%]            $6.4 B              Seretide/Advair [$6.9 B]
                                                                                                                       Lamictal [$2.2 B]
                                                                                                                       Valtrex [$1.9 B]

      3   [3]
                          Sanofi-Aventis
                          Paris, France [sanofi-aventis.com]
                                                                        $36.9 B [-1.4%]            $6.5 B              Lovenox [$3.8 B]
                                                                                                                       Plavix [$3.5 B]
                                                                                                                       Lantus [$3.0 B]

      4   [4]
                          Novartis
                          Basel, Switzerland [novartis.com]
                                                                        $32.2 B [9.3%]             $6.4 B              Diovan [$5.0 B]
                                                                                                                       Gleevec [$3.1 B]
                                                                                                                       Zometa [$1.3 B]

      5   [5]
                          AstraZeneca
                          London, England [astrazeneca.com]
                                                                        $28.7 B [11.5%]            $5.1 B              Nexium [$5.2 B]
                                                                                                                       Seroquel [$4.0 B]
                                                                                                                       Crestor [$2.8 B]

      6   [6]
                          Johnson & Johnson
                          New Brunswick, NJ [jnj.com]
                                                                        $24.9 B [7.0%]             $5.3 B              Remicade [$4.7 B]
                                                                                                                       Procrit [$2.9 B]
                                                                                                                       Topamax [$2.5 B]

      7   [7]
                          Merck
                          Whitehouse Station, NJ [merck.com]
                                                                        $24.2 B [6.9%]             $4.9 B              Singulair [$4.2 B]
                                                                                                                       Cozaar/Hyzaar [$3.4 B]
                                                                                                                       Fosamax [$3.0 B]

      8   [8]
                          Roche
                          Basel, Switzerland [roche.com]
                                                                        $20.3 B [20.3%]            $6.7 B              MabThera/Rituxan [$4.9 B]
                                                                                                                       Herceptin [$4.3 B]
                                                                                                                       Avastin [$3.6 B]

      9   [10]
                          Wyeth
                          Madison, NJ [wyeth.com]
                                                                        $18.6 B [18.8%]            $3.1 B              Effexor [$3.8 B]
                                                                                                                       Prevnar [$2.4 B]
                                                                                                                       Enbrel [$2.0 B]

      10        [9]
                          Eli Lilly
                          Indianapolis, IN [lilly.com]
                                                                        $17.6 B [19.0%]            $3.5 B              Zyprexa [$4.8 B]
                                                                                                                       Cymbalta [$2.1 B]
                                                                                                                       Gemzar [$1.6 B]

     [Key Insights on the Top 10]
     Pfizer: Shares hit a 10-year low       GlaxoSmithKline: Cuts cost of       AstraZeneca: In February, lung           Merck: Vytorin gets slammed
     in April 2008 with profit falling      AIDS medication to impoverished     cancer drug Recentin failed to           in the press after a study reveals
     18 percent // Voluntarily pulls        countries // NIH trial reveals      meet its endpoint in clinical trials     that it is no better than generics
     popular Lipitor ads after it was       that Avandia does not lead to       // FDA concludes that Prilosec           for reducing arterial plaque //
     revealed that spokesperson             heart risks // Purchases Reliant    and Nexium do not lead to heart          In January, a federal grand jury
     Dr. Jarvik was not a licensed          Pharma for $1.65 billion //         problems // Study reveals that           investigates Merck for off-label
     cardiologist // Chantix comes          Avandia receives black box for      Crestor does not reduce the risk         promotion of Vioxx
     under fire as people blog about        heart attacks // Andrew Witty is    of death in older people that
     adverse reactions; Pfizer beefs up     named CEO in October 2007           suffer from heart failure                Lilly: The company is slammed
     warnings // Viagra turns 10 //                                                                                      with lawsuits claiming it withheld
     announces in January that it will      Sanofi-Aventis: Plavix patent       Johnson & Johnson: Sued                  Zyprexa’s side effects
     cut 10,000 jobs // Exhubera is         upheld in New York court, generic   by Arkansas over marketing of
     voluntarily pulled off the market      sales by Apotex halted              Risperdal // Launches DTC ad             Wyeth: Pristiq approved for
                                                                                campaign for Cordis drug-eluting         depression // Releases generic
     Roche: Avastin is approved for         Novartis: In December Novartis      stents // Establishes three new          version of heartburn drug Protonix
     breast cancer // Roche’s Tamiflu       announced that it would axe         divisions to handle surgical             // Announces that it will cut
     receives stronger psychiatric          2,500 full time jobs // Ludwig      technologies, chronic conditions,        5,000 employees over
     warning // Judge temproarily           Hantson is named CEO of             and potential growth areas //            three years
     halts sales of Mircera until lawsuit   Novartis North America // Pays      Settles Ortho-Evra suit for
     with Amgen over Aranesp patents        $11 billion for Nestle’s eye care   $1.25 million
     ends // In January, Roche picked       division Alcon
     up Ventana for $3.4 billion //
     Recalls AIDS drug Viracept



Nothing works                          for you like a network that works together                                                     THE AUTHENTIC INTEGRATED NETWORK
78
            PE50
     PHARMACEUTICAL EXECUTIVE                                                                                                       MAY 2008 www.pharmexec.com




      Rank                 Company & Headquarters                         2007 Global Pharma R&D Spend                      2007 Top-Selling Drugs
      [‘06 Rank]           [Web site]                                     Sales [change from 2006]                          [2007 sales]


      11       [11]
                           Bristol-Myers Squibb
                           New York, NY [bms.com]
                                                                          $15.6 B [12.7%]                  $3.3 B           Plavix [$4.8 B]
                                                                                                                            Abilify [$1.7 B]
                                                                                                                            Avapro/Avalide [$1.2 B]

      12       [15]
                           Bayer
                           Leverkusen, Germany
                                                                          $15.0 B [51.9%]                  $3.8 B           Yasmin [$1.5 B]

                           [bayer.com]

      13       [13]
                           Abbott
                           Abbott Park, IL [abbott.com]
                                                                          $14.6 B [18.0%]                  $2.5 B           Humira [$3.0 B]



      14       [12]
                           Amgen
                           Thousand Oaks, CA [amgen.com]
                                                                          $14.3 B [3.3%]                   $3.2 B           Aranesp [$3.6 B]



      15       [14]
                           Boehringer-Ingelheim
                           Ingelheim, Germany
                                                                          $12.6 B [15.4%]                  $2.4 B           Spiriva [$2.6 B]

                           [boehringer-ingelheim.com]


     TOP 10 US PRODUCTS OF 2007                                                                                                                                                                             GLO
     Product [Maker]                        2007 Sales in billions                                                  Growth in Sales                                                                         Percen
     1. Lipitor [Pfizer]                                                                                    $8.1     -6.9%
     2. Nexium [AstraZeneca]                                                  $5.5                                       5.8%
     3. Advair Diskus [GlaxoSmithKline]                                $4.3                                                7.5%
     4. Plavix [Sanofi-Aventis/BMS]                                    $3.9                                                                            30%
     5. Seroquel[AstraZeneca]                                       $3.5                                                             16.7%
                                                                                                  was                                                                                                         45.
                                                                                             %
     6. Singulair[Merck]                                          $3.4                                                           13.3%
                                                                                           Plavix

                                                                                        UP 30




                                                                                                                                                                 SOURCE: IMS Heatlh
     7. Enbrel[Amgen/Wyeth]                                       $3.4                                                         9.7%
     8. Prevacid[Tap Pharmaceuticals]                             $3.4                                              -5.6%
     9. Aranesp [Amgen]                                          $3.2                             2007              -20%
     10. Epogen [Amgen]                                          $3.1                                               -3.1%

     TOP 10 GLOBAL PRODUCTS OF 2007                                                                                                                                                                          The
     Product [Maker]                        2007 Sales in billions                                                  Growth in Sales                                                                          ma
     1. Lipitor [Pfizer]
     2. Plavis [Sanofi-Aventis/BMS]                                        $7.3
                                                                                                           $13.5       -2.8%
                                                                                                                                              20.5%                                                          6
     3. Nexium [AstraZeneca]                                             $7.2                                           5.3%                                                                                 to a




                                                                                                                                                                 SOURCE: MIDAS, AT Dec 2007
                                                                                                                                                                                                             $c
     4. Seretide/Advair [GlaxoSmithKline]                              $7.1                                                 9.6%
                                                                                             th
     5. Enbrel [Amgen/Wyeth]                                         $5.3             l grow                                          15.3%
                                                                                 Glo f Plavix
                                                                                      %
                                                                                 UP 20
                                                                                                                                                                                M
     6. Zyprexa [Lilly]                                              $5.0           o                                1.9%
                                                                                                                                                                                                             at
     7. Risperdal [Janssen-Ortho]                                   $4.9                                               4.4%
                                                                                             7                                                                                                               exc
                                                                                       in 200
     8. Seroquel [AstraZeneca]                                     $4.6                                                               16.2%


                                                                                                                                                                      IMS
     9. Singulair [Merck]                                         $4.5                                                               14.7%
     10. Aranesp [Amgen]                                         $4.4                                                 -12.9%




      16 COMPANIES BY US SALES
            Schering-Plough                                               $10.2 B [18.8%]                  $2.9 B           Remicade [$1.6 B]



                                                                                                                        [3.8%]
               [17]
            Kenilworth, NJ [                     schering-plough.com]
     TOP 10                                                                                                                                                                                                 TOP
      17 Takeda [
     Company
     1. Pfizer [16]
                             Total Sales US billions                      $9.73 B [12.1%]                  $1.6 B           Lansoprazole [$3.4 B]
                                                                                                                                                                                                            Thera
                                                                                                                                                                 SOURCE: IMS Heatlh, MIDAS, December 2007




            Osaka, Japan                     takeda.com]                                                 $23.5
                                                                                                                                                                                                            Oncolo
     2. GlaxoSmithKline                                                               $20.1

      18 Genentech CA [                                                   $9.44 B [23.6%]                  $2.4 B           Avastin [$2.3 B]                                                                Lipid r
     3. Merck                                                       $17.6
               [19]
                                                                                                                              AMOUNT SALES GREW                                                             Respir
            South San Francisco,
     4. Johnson & Johnson                                 gene.com]
                                                                 $16.3
                                                                                                                               IN THE US FOR 2007.                                                          Acid p
     5. AstraZeneca                                          $15.5

      19 Teva Tikva, Israel                                               $9.41 B [20.3%]                  $581 M             TOTAL [$1.7 B]
                                                                                                                            Copaxone US SALES WERE                                                          Antidia
     6. Amgen                                               $14.3
                                                                                                                                                                                                            Antips
               [18]
            Petach
     7. Novartis                                           $13.9                                                                 $286.5 BILLION,                                                            Antide
     8. Hoffman-Laroche
            [             tevapharm.com]                $12.3                                                                    COMPARED WITH                                                              Angiot
     9. Sanofi-Aventis                                 $10.9
                                                                                                                             $276.1 BILLION IN
                                                                                                                            Human insulins [$2.6 B]2006
      20 Novo Nordisk
                                                                                                                                                                                                            Anti-ep
     10. Lilly                                       $10.3                $8.19 B [19.6%]                  $1.2 B                                                                                           Autoim
               [22]
            Bagsvaerd, Denmark

      [25]     [novonordisk.com]             LOST FROM THE LIST
                    Generics market hits
                    $64.5B, with growth
                    of 11%, compared to
                                             Four top 50 companies and three near-misses were acquired last year:
                                             Schering AG (last year number 20, bought by Bayer)
                                             Altana, last year 29, bought by Nycomed                                                                                                                            [
Nothing works for you
    THE NUMBER                                                                                works together
                                  like a network that 36,BioSciences unit, KGaA 37, bought by Schering-Plough
                    5% total market growth
                                             Serono, last year’s     bought by Merck
                                                                                                                                                                 E: IMS (left)




                                             Akzo Nobel’s Organon                    last year’s
             OF NEW                                                                                       THE AUTHENTIC INTEGRATED NETWORK
                                                                          Tanabe Seiyaku, bought by Mitsubishi
              NCEs
                                                GLOBAL PHARMACEUTICAL SALES BY REGION, 2007

                                                       PE50
                                                Percent of Global Sales        Market                           2007 Sales (US$B)                               % Growth from 2006
                                                                               North America                                                       $304.5               4.2%
                                           80   PHARMACEUTICAL EXECUTIVE       Europe                                                   $206.2                           MAY 2008 www.pharmexec.com
                                                                                                                                                                              6.7%
                                                                               Japan                                   $62.2                                                                 13.1%
                                                                 31.1%         Asia*, Africa, and Australia          $58.5                                              4.2%
                                                                               Latin America                       $32                                                                     12%
                                                  45.9%                        *Excluding Japan                                                                              SOURCE: IMS MIDAS, MAT December 2007
SOURCE: IMS Heatlh




                                                                   9.4%


                                                                                              [31]
                                                 Rank                Company & Headquarters                            TOP 10 Pharma R&D Spend 2007 Top-Selling Drugs
                                                                                                                    2007 Global R&D SPEND
                                                 [‘06 Rank]      8.8% site]
                                                                     [Web                                           Sales [change from 2006] Total R&D Spend US[2007 sales]
                                                                                                                       Company                                  billions
                                                              4.8%                                                      1. Pfizer                                                                     $8.1

                                                 21 Tokyo, Japan [ PERCENT




                                                                                                                                                                                                                    SOURCE: PHARM EXEC 50 (right); IMS (left)
                                                              Astellas
                                                 The global pharmaceutical
                                                                                                                    $7.82 B [10.2%]
                                                                                                                      2. Roche                   $1.4 B           Prograf [$1.5 B]     $6.7
                                                          [21]                         astellas.com]                    3. Sanofi-Aventis                                              $6.6
                                                 market grew by                                                         4. Novartis                                                $6.4

                                                 6.4 Daiichi Sankyo OF EMERGING
                                                 22 percent [ MARKETS’ SHARE $7.12 B
                                                          [23]
                                                      Tokyo, Japan
                                                 to approximately
                                                                                       daiichisankyo.com]
                                                                                                                        5. GSK
                                                                                                                        6. J&J
                                                                                                                        7. AstraZeneca
                                                                                                                                      [4.7%]     $1.5 B           Olmesartan
                                                                                                                                                                        $5.3
                                                                                                                                                                       $5.1
                                                                                                                                                                                [$1.4 B]
                                                                                                                                                                                   $6.4




                                                 23 billion, OF[ GROWTH IN $6.11 B
SOURCE: MIDAS, AT Dec 2007




                                                 $712 Merck KGaA THE GLOBAL                                                                      $1.7 B
                                                                                                                        8. Merck [24.5%]                             $4.9
                                                          [24]                                                          9. Bayer                                 $3.8 [$1.8 B]
                                                      Darmstadt, Germany                          merck.de]                                                      Rebif
               M




                                                                                                                        10. Eli Lilly                          $3.5
                                                 at constant
                                                 24 Eisai Japan [ PHARMACEUTICAL $5.55 B
                                                 exchange rates
                                                          [25]
                                                                                                                                    [14.5%]      $921 M
                                                                                                                                                                  Aricept [$2.3 B]
                                                                                                                                                                           [25.5%]
     IMS




                                                      Tokyo,             MARKET        eisai.co.jp]                      U.S. MARKET’S CONTRIBUTION

                                                 25 Otsuka [                     $5.27 B                                 TO GLOBAL GROWTH
                                                                                                                               [27.4%]  N/A       N/A
                                                          [26]                                                           —ITS LOWEST EVER
                                                      Tokyo, Japan                     otsuka-global.com]




                                                TOP THERAPEUTIC CLASSES BY GLOBAL SALES
                                                Therapeutic Class                     2007 Sales in Billions*                                               *Exludes unaudited markets, and Russia,
SOURCE: IMS Heatlh, MIDAS, December 2007




                                                Oncologics                                                                                       $41.4      Ukraine and Belarus audited data. Sales
                                                Lipid regulators                                                                    $33.7                   cover direct and indirect pharmaceutical
                                                Respiratory agents                                                               $28.6                      channel purchases in US dollars from
                                                Acid pump inhibitors                                                        $25.6                           pharmaceutical wholesalers and
                                                                                                                                                            manufacturers. The figures include
                                                Antidiabetics                                                              $24.1
                                                                                                                                                            prescription and certain over-the-counter
                                                Antipsychotics                                                          $20.7                               data and represent manufacturer prices.




                                                                                                                                                                                                                     SOURCE: IMS Health
                                                Antidepressants                                                        $19.7
                                                Angiotensin II antagonists                                            $19.4
                                                Anti-epileptics                                                   $15.2
                                                Autoimmune agents                                               $13.3




                                                     [19]                      THE DOLLAR AMOUNT OF
                                                                                 BRANDED PRODUCTS                            [2.8]                       ONCOLOGICS WAS THE
                                                                                                                                                         FASTEST-GROWING
                                                                                                                                                         CATEGORY, UP
                                                    PERCENT                    LIKELY TO BE EXPOSED TO
                                                                                                                                                     [14]
SOURCE: IMS (left)




                                                                                                                               PERCENT THAT
                                                     OF TOTAL                     GENERICS IN 2008                              VOLUME OF

                                                                             [$13 B]
                                                 PRESCRIPTIONS                                                                 PRESCRIPTION


                                                                                                                                                                                                                     SOURCE: IMS Health
                                                   DISPENSED                                                                    SALES ROSE               PERCENT.
                                                    THROUGH
                                                MEDICARE PART D




                                                 26                  Servier
                                                                     Neuilly-sur-Seine, France [servier.com]
                                                                                                                    $5.11 B [17.4%]              $1.0 B           N/A



                                                 27       [30]
                                                                     UCB
                                                                     Brussels, Belgium [ucb-group.com]
                                                                                                                    $4.66 B [61.1%]              $1.2 B           Keppra [$1.5 B]



                                                 28       [27]
                                                                     Baxter
                                                                     Deerfield, IL [baxter.com]
                                                                                                                    $4.65 B [19.8%]              $760 M           Advate [$1.2 B]



                                                 29       [48]
                                                                     Nycomed
                                                                     Zurich, Switzerland [nycomed.com]
                                                                                                                    $4.35 B
                                                                                                                    [190.1%]
                                                                                                                                                 $415 M           Pantoprazole [$2.5 B]



                                                 30       [28]
                                                                     Solvay
                                                                     Brussels, Belgium [solvay.com]
                                                                                                                    $3.78 B [10.3%]              $606 M           Tricor/Lipanthyl [$632 M]




                                           Nothing works                     for you like a network that works together                                                            THE AUTHENTIC INTEGRATED NETWORK
     TOP 10 US PRODUCTS OF 2007                                                                                                                                                                                GLO

            PE50
     Product [Maker]                    2007 Sales in billions                                                  Growth in Sales                                                                                Percen
82   1. Lipitor [Pfizer] EXECUTIVE
     PHARMACEUTICAL
                                                                                                        $8.1    -6.9%
                                                                                                                              MAY 2008 www.pharmexec.com
     2. Nexium [AstraZeneca]                                              $5.5                                       5.8%
     3. Advair Diskus [GlaxoSmithKline]                              $4.3                                               7.5%
     4. Plavix [Sanofi-Aventis/BMS]                                 $3.9                                                                    30%
     5. Seroquel[AstraZeneca]                                    $3.5                                                            16.7%
                                                                                             was                                                                                                                 45.
                                                                                     %
     6. Singulair[Merck]                                        $3.4                                                        13.3%
                                                                                      Plavix

                                                                                UP 30 $591 M




                                                                                                                                                                    SOURCE: IMS Heatlh
      Rank
     7. Enbrel[Amgen/Wyeth]Company & Headquarters               $3.4     2007 Global Pharma             R&D Spend 2007 Top-Selling Drugs
                                                                                                                         9.7%
      [‘06 Rank]           [Web site]
     8. Prevacid[Tap Pharmaceuticals]                           $3.4     Sales [change from 2006]               -5.6% [2007 sales]
     9. Aranesp [Amgen]                                        $3.2                          2007               -20%

      31 GLOBAL PRODUCTS OF 2007
     TOP 10
             Gilead Sciences
     10. Epogen [Amgen]
               [35]
             Foster City, CA [                    gilead.com]
                                                              $3.1        $3.73 B      [44.1%]                  -3.1% Truvada [$1.6 B]

                                                                                                                                                                                                                The
      32 Genzyme MA [
     Product [Maker]
                 [34]
             Cambridge,
     1. Lipitor [Pfizer]
                                            2007 Sales in billions
                                                   genzyme.com]
                                                                          $3.22 B [22.6%]               $738 M Cerezyme [$1.1 B]
                                                                                                        $13.5
                                                                                                              Growth in Sales
                                                                                                                        -2.8%
                                                                                                                                                                                                                ma
                                                                                                                                                                                                                6
      33 Forest NY [
     2. Plavis [Sanofi-Aventis/BMS]                                       $7.3
                                                                          $3.18 B [14.1%]               $941 M             Lexapro [$2.1 20.5%
                                                                                                                                         B]
     3. Nexium [AstraZeneca]                                            $7.2                                             5.3%                                                                                   to a




                                                                                                                                                                    SOURCE: MIDAS, AT Dec 2007
                 [31]
             New York,
                                                                                                                                                                                                                $c
     4. Seretide/Advair [GlaxoSmithKline]       frx.com]             $7.1
                                                                                         th                                  9.6%
                                                                                   l grow
      34 Menarini [
     5. Enbrel [Amgen/Wyeth]                                        $5.3                                                            15.3%
                                                                             Glo f lav
                                                                          $3.14 PBix[10.9%]             $350 M 1.9%N/A
                                                                                20%




                                                                                                                                                                                   M
     6. Zyprexa [Lilly]                                             $5.0        o
                                                                                                                                                                                                                at
             Florence, Italy
     7. Risperdal [Janssen-Ortho]                  menarini.com] $4.9
                                                                            UP B [17.6%]  7
                                                                                                                        4.4%
                                                                                                                                                                                                                exc

      35 Allergan[                                                                  in 200
     8. Seroquel [AstraZeneca]                                    $4.6                                                               16.2%




                                                                                                                                                                         IMS
     9. Singulair [Merck]                                        $4.5     $3.11                         $718 M             Botox [$1.2 B]
                                                                                                                                  14.7%
                 [33]
             Irvine, CA
     10. Aranesp [Amgen]                    allergan.com]       $4.4                                                   -12.9%




     TOP 10 COMPANIES BY US SALES
     Company                    Total Sales US billions
                                                                                                                         [3.8%]                                                                                TOP
                                                                                                                                                                                                               Therap




                                                                                                                                                                    SOURCE: IMS Heatlh, MIDAS, December 2007
     1. Pfizer                                                                                       $23.5
                                                                                                                                                                                                               Oncolo
     2. GlaxoSmithKline                                                            $20.1
                                                                                                                                                                                                               Lipid r
     3. Merck                                                           $17.6
     4. Johnson & Johnson                                             $16.3
                                                                                                                             AMOUNT SALES GREW                                                                 Respir
     5. AstraZeneca                                               $15.5                                                       IN THE US FOR 2007.                                                              Acid pu
     6. Amgen                                                    $14.3                                                       TOTAL US SALES WERE                                                               Antidia
                                                                                                                                                                                                               Antips
     7. Novartis                                                $13.9                                                           $286.5 BILLION,                                                                Antide
     8. Hoffman-Laroche                                      $12.3                                                              COMPARED WITH                                                                  Angiot
     9. Sanofi-Aventis                                      $10.9
     10. Lilly                                            $10.3
                                                                                                                            $276.1 BILLION IN 2006                                                             Anti-ep
                                                                                                                                                                                                               Autoim




      [25]
                                                                          LOST FROM THE LIST
                                 Generics market hits
                                 $64.5B, with growth
                                 of 11%, compared to
                                                                          Four top 50 companies and three near-misses were acquired last year:
                                                                          Schering AG (last year number 20, bought by Bayer)
                                                                          Altana, last year 29, bought by Nycomed
                                                                          Serono, last year’s 36, bought by Merck KGaA
                                                                                                                                                                                                                   [
         THE NUMBER              5% total market growth




                                                                                                                                                                    SOURCE: IMS (left)
                                                                          Akzo Nobel’s Organon BioSciences unit, last year’s 37, bought by Schering-Plough
           OF NEW                                                         Tanabe Seiyaku, bought by Mitsubishi
             NCEs                                                         MedImmune, bought by AstraZeneca
          THAT WERE                                                       Schwarz Pharma, bought by UCB
                                                                                                                                                                                                                PRE
          LAUNCHED                                                                                                                                                                                                D
           IN 2007
                                                                                                                                                                                                               MED




      36       [43]
                           Mitsubishi Tanabe
                           Osaka, Japan [mt-pharma.co.jp]
                                                                          $2.99 B [73.3%]               $644 M             Radicut [$2.4 B]



      37       [32]
                           Chugai
                           Tokyo, Japan [chugai-pharm.co.jp]
                                                                          $2.98 B [9.2%]                $485 M             Epogin [$491 M]



      38                   P&G
                           Cincinnati, Ohio [pg.com]
                                                                          $2.91 B
                                                                                                        N/A
                                                                                                                           Actonel [$791 M]



      39                   Ratiopharm
                           Ulm, Germany [ratiopharm.com]
                                                                          $2.49 B                       N/A                Generics [N/A]



      40       [39]
                           CSL
                           Victoria, Australia [csl.com.au]
                                                                          $2.43 B [23.3%]               $159 M             N/A




Nothing works                        for you like a network that works together                                                             THE AUTHENTIC INTEGRATED NETWORK
                                           84
                                                       PE50
                                                PHARMACEUTICAL EXECUTIVE                                                                                                           MAY 2008 www.pharmexec.com




                                                 Rank                Company & Headquarters                           2007 Global Pharma R&D Spend                        2007 Top-Selling Drugs
                                                 [‘06 Rank]          [Web site]                                       Sales [change from 2006]                            [2007 sales]


                                                 41                  Barr Pharmaceuticals
                                                                     Montvale, NJ [barrlabs.com]
                                                                                                                      $2.33 B [61.6%]                 $248 M              Seasonale [$100 M]



                                                 42       [38]
                                                                     Alcon
                                                                     Hünenberg, Switzerland [alcon.com]
                                                                                                                      $2.31 B [15.1%]                 $564 M              N/A



                                                 43                  Mundipharma
                                                                     Cambridge, England
                                                                                                                      $2.18 B                         N/A                 N/A

                                                                     [mundipharma.co.uk]

                                                 44       [47]
                                                                     Shire
                                                                     Hampshire, England [shire.com]
                                                                                                                      $2.17 B [40.9%]                 $567 M              Adderall XR [$1.0 B]



                                                 45       [42]
                                                                     Biogen Idec
                                                                     Cambridge, MA [biogenidec.com]
                                                                                                                      $2.14 B [20.0%]                 $925 M              Avonex [$1.9 B]
                                                                                                                                                                                 0              2               4                                                       6




                                                GLOBAL PHARMACEUTICAL SALES BY REGION, 2007
                                                Percent of Global Sales           Market                         2007 Sales (US$B)                                     % Growth from 2006
                                                                                  North America                                                           $304.5               4.2%
                                                                                  Europe                                                    $206.2                                   6.7%
                                                                                  Japan                                 $62.2                                                                                   13.1%
                                                                 31.1%            Asia*, Africa, and Australia        $58.5                                                     4.2%
                                                                                  Latin America                     $32                                                                                      12%
                                                  45.9%                           *Excluding Japan                                                                                   SOURCE: IMS MIDAS, MAT December 2007
SOURCE: IMS Heatlh




                                                                   9.4%


                                                                                                 [31]
                                                                                                                         TOP 10 R&D SPEND
                                                                 8.8%                                                    Company                     Total R&D Spend US billions
                                                              4.8%                                                       1. Pfizer                                                                            $8.1




                                                                                                                                                                                                                            SOURCE: PHARM EXEC 50 (right); IMS (left)
                                                                                                                         2. Roche                                                                 $6.7
                                                 The global pharmaceutical                                               3. Sanofi-Aventis                                                        $6.6
                                                 market grew by                                                          4. Novartis                                                          $6.4
                                                                                                    PERCENT
                                                 6.4 percent                                      OF EMERGING
                                                                                                                         5. GSK
                                                                                                                         6. J&J                                                $5.3
                                                                                                                                                                                              $6.4

                                                 to approximately                                MARKETS’ SHARE          7. AstraZeneca                                      $5.1
SOURCE: MIDAS, AT Dec 2007




                                                 $712 billion,
                                                                                                                         8. Merck                                           $4.9
                                                                                                  OF GROWTH IN           9. Bayer                                       $3.8
                                                                                                   THE GLOBAL
               M




                                                                                                                         10. Eli Lilly                                $3.5
                                                 at constant
                                                 exchange rates                                 PHARMACEUTICAL
                                                                                                                                                                                     [25.5%]
     IMS




                                                                                                     MARKET               U.S. MARKET’S CONTRIBUTION
                                                                                                                          TO GLOBAL GROWTH
                                                                                                                          —ITS LOWEST EVER




                                                TOP THERAPEUTIC CLASSES BY GLOBAL SALES
                                                 46       Stada
                                                Therapeutic Class                   2007 Sales in Billions*           $2.13 B [37.9%]                       M Omeprazole [$1.6 B]
                                                                                                                                                      $56.9 *Exludes unaudited markets, and Russia,
SOURCE: IMS Heatlh, MIDAS, December 2007




                                                Oncologics            Bad Vilbel, Germany [stada.de]                                                   $41.4       Ukraine and Belarus audited data. Sales


                                                 47
                                                Lipid regulators                                                                $33.7                              cover direct and indirect pharmaceutical
                                                Respiratory agents
                                                                     King Pharmaceuticals                                    $28.6
                                                                                                                                                                          Altace [$646 M]
                                                                                                                                                                   channel purchases in US dollars from
                                                           [40]
                                                Acid pump inhibitors Bristol, TN [kingpharm.com]                      $2.04 B
                                                                                                                        $25.6 [8.0%]                  $184 M       pharmaceutical wholesalers and
                                                                                                                                                                   manufacturers. The figures include

                                                 48
                                                Antidiabetics                                                          $24.1
                                                Antipsychotics
                                                                     Lundbeck                                         $2.03 B
                                                                                                                    $20.7
                                                                                                                              [22.4%]                 $429 M              Cipralex [$802 M]
                                                                                                                                                                   prescription and certain over-the-counter
                                                           [45]                                                                                                    data and represent manufacturer prices.
                                                                      Copenhagen, Denmark [lundbeck.com]
                                                                                                                                                                                                                             SOURCE: IMS Health




                                                Antidepressants                                                    $19.7


                                                 49
                                                Angiotensin II antagonists                                        $19.4
                                                Anti-epileptics      Actavis                                  $15.2   $1.79 B [27.6%]                 $97.5 M             Gabapentin [$69 M]
                                                           [50]
                                                Autoimmune agents Hafnarfjordur, Iceland [actavis.com]      $13.3


                                                 50                  Watson                                           $1.78 B [-4.1%]                 $145 M              N/A


                                                    [19]                                                                      [2.8]
                                                          [41]       Corona, CA [watson.com]
                                                                                  THE DOLLAR AMOUNT OF                                                         ONCOLOGICS WAS THE
                                                                                    BRANDED PRODUCTS                                                           FASTEST-GROWING
                                                PERCENT                                                                                                        CATEGORY, UP
                                                                                  LIKELY TO BE EXPOSED TO
                                                              works for you                                                           works together
                                                                                                                                                             [14]
URCE: IMS (left)




                                           Nothing TOTAL                                                    PERCENT THAT
                                                OF                                           like 2008
                                                                                     GENERICS IN a network that
                                                                                                             VOLUME OF                                                                      THE AUTHENTIC INTEGRATED NETWORK

                                             PRESCRIPTIONS
                                                                                                                                                                                                                             h

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:3
posted:1/15/2013
language:Unknown
pages:7